Considering the frequent lineage switches and sensitivity to both ALL- and AML-directed schemes, a uniform strategy directed at both lymphoid and myeloid lineages or at hematopoietic stem cells may be better for <i>TCF3-ZNF384</i>-positive leukemia. The gene discussed is TCF3; the disease is acute myeloid leukemia.